Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

The pharmaceutical industry spends a ton of money on drug ads. This should come as no surprise to anyone who watches TV or ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...